Biomedical Journal最新文献

{"title":"A long term bone and renal safety of TAF treatment on renal transplant recipients.","authors":"Desmond Y H Yap, Cheng-Kun Wu, Colin Tang, Kuo-Chin Chang, Wen-Chin Lee, David T W Lui, Maggie K M Ma, Tsung-Hui Hu, Tak Mao Chan","doi":"10.1016/j.bj.2025.100833","DOIUrl":"https://doi.org/10.1016/j.bj.2025.100833","url":null,"abstract":"<p><strong>Rationale & objective: </strong>The data on tenofovir alafenamide (TAF) in kidney transplant recipients (KTRs) with chronic hepatitis B virus (HBV) infection is limited.</p><p><strong>Study design: </strong>Retrospective cohort study SETTING & STUDY POPULATIONS: HBsAg-positive KTRs who received TAF between 2019 and 2022 were included in the analysis, categorized into treatment-naïve and treatment-experienced groups. Additionally, a subgroup of patients receiving ETV was analyzed for comparison.</p><p><strong>Results: </strong>Four treatment-naïve (Group I) and 35 treatment-experienced (Group II) patients received TAF for 26.4±11.3 and 43.7±19.0 months, respectively. Both groups showed significant HBV DNA reduction, but Group I achieved higher rates of undetectable HBV DNA (50%, 75%, 75%, 100% at 6, 12, 24, 30 months, compared with 16.7%, 25.3%, 31.4%, 34.7% in Group II, p=0.018). Renal allograft function remained stable during follow-up, and bone toxicity was minimal. For ETV, 10 patients demonstrated excellent viral suppression (HBV DNA undetectable in 70% at 48 weeks and 100% at 96 weeks) with stable renal function over a median of 5.2 years.</p><p><strong>Limitations: </strong>Retrospective study with a lack of prospective comparison of TAF and ETV.</p><p><strong>Conclusions: </strong>Our results suggest that TAF provides favorable efficacy, renal safety, and tolerability in KTRs. ETV also provided effective and sustainable viral suppression. TAF may offer additional advantages such as no concern of viral resistance and dose adjustment by eGFR levels for long-term management of HBsAg-positive KTRs.</p>","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":" ","pages":"100833"},"PeriodicalIF":4.1,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143432305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Olesoxime protects against cisplatin-induced acute kidney injury by attenuating mitochondrial dysfunction","authors":"Peipei Wang ,&nbsp;Jing Ouyang ,&nbsp;Kaiqian Zhou ,&nbsp;Dandan Hu ,&nbsp;Shengnan Zhang ,&nbsp;Aihua Zhang ,&nbsp;Yunwen Yang","doi":"10.1016/j.bj.2024.100730","DOIUrl":"10.1016/j.bj.2024.100730","url":null,"abstract":"<div><h3>Background</h3><div>Mitochondrial dysfunction is a critical factor in the pathogenesis of acute kidney injury (AKI). Agents that ameliorate mitochondrial dysfunction hold potential for AKI treatment. The objective of this study was to investigate the impact of olesoxime, a novel mitochondrial-targeted agent, on cisplatin-induced AKI.</div></div><div><h3>Methods</h3><div>In vivo, a cisplatin-induced AKI mouse model was established by administering a single intraperitoneal dose of cisplatin (25 mg/kg) to male C57BL/6 mice for 72 hours, followed by gavage of either olesoxime or a control solution. In vitro, human proximal tubular HK2 cells were cultured and subjected to treatments with cisplatin, either in the presence or absence of olesoxime.</div></div><div><h3>Results</h3><div>In vivo, our findings demonstrated that olesoxime administration significantly mitigated the nephrotoxic effects of cisplatin in mice, as evidenced by reduced blood urea nitrogen (BUN) and serum creatinine (SCr) levels, improved renal histopathology, and decreased expression of renal tubular injury markers such as kidney injury molecule 1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL). Furthermore, olesoxime administration markedly reduced cisplatin-induced apoptosis, inflammation, and oxidative stress in the kidneys of AKI mice. Additionally, olesoxime treatment effectively restored mitochondrial function in the kidneys of AKI mice. I<em>n vitro</em>, our results indicated that olesoxime treatment protected against cisplatin-induced apoptosis and mitochondrial dysfunction in cultured HK2 cells. Notably, cisplatin's anticancer effects were unaffected by olesoxime treatment in human cancer cells.</div></div><div><h3>Conclusion</h3><div>The results of this study suggest that olesoxime is a viable and efficient therapeutic agent in the treatment of cisplatin-induced acute kidney injury presumably by alleviating mitochondrial dysfunction.</div></div>","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":"48 1","pages":"Article 100730"},"PeriodicalIF":4.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140775899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Ex vivo cultivation model for circulating tumor cells: The success rate and correlations with cancer response to therapy","authors":"I-Hsuan Chiang ,&nbsp;Hsuan-Chih Kuo ,&nbsp;Chun-Ta Liao ,&nbsp;Yung-Chia Kuo ,&nbsp;Shao-Ming Yu ,&nbsp;Hung-Ming Wang ,&nbsp;Yi-Hui Huang ,&nbsp;Kim Anh Nguyen Thi ,&nbsp;Min-Hsien Wu ,&nbsp;Jason Chia-Hsun Hsieh","doi":"10.1016/j.bj.2024.100819","DOIUrl":"10.1016/j.bj.2024.100819","url":null,"abstract":"<div><h3>Background</h3><div>Cancer mortality is closely linked to recurrence and distant metastasis, posing challenges in real-time tracking due to the invasiveness of current methods. Circulating tumor cells (CTCs) show promise as potential tools; however, their scarcity remains a significant obstacle.</div></div><div><h3>Method</h3><div>In this prospective study, we validated a simple culture protocol and investigated the correlation between clinical response and CTC growth status. Following negative selection, the isolated cells <em>were subjected to ex vivo</em> cultivation in a two-dimensional environment supplemented with cytokines for up to 21 days, followed by immunofluorescence staining for analysis.</div></div><div><h3>Results</h3><div>Among 37 participants with solid tumors and distant metastasis (34.8% head and neck cancer), 47 samples were collected, from which CTCs were detected. The percentages of CTCs, atypical CTCs, and white blood cells during cultivation from days 7–21 were significantly different (<em>p</em> &lt; 0.001, <em>p</em> &lt; 0.001, and <em>p</em> = 0.330, respectively). Patients were further categorized into progressive disease (PD) and non-PD groups based on disease status, revealing significant differences in CTC growth rates, which increases from Days 7–21 between groups (5.5x vs. 2.8x growth, respectively; <em>p</em> &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>With the proposed protocols, we cultured CTCs from patients with various cancers for 21 days and identified a tool for predicting cancer response. The actual cancer status (PD or non-PD) at CTC isolation correlates to CTC growth rate, guiding the required observation time and parameters for culture.</div></div>","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":"48 1","pages":"Article 100819"},"PeriodicalIF":4.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11743102/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-throughput proteomics-guided biomarker discovery of hepatocellular carcinoma","authors":"Dongyoon Shin ,&nbsp;Yeongshin Kim ,&nbsp;Junho Park ,&nbsp;Youngsoo Kim","doi":"10.1016/j.bj.2024.100752","DOIUrl":"10.1016/j.bj.2024.100752","url":null,"abstract":"<div><div>Liver cancer stands as the fifth leading cause of cancer-related deaths globally. Hepatocellular carcinoma (HCC) comprises approximately 85%–90% of all primary liver malignancies. However, only 20–30% of HCC patients qualify for curative therapy, primarily due to the absence of reliable tools for early detection and prognosis of HCC. This underscores the critical need for molecular biomarkers for HCC management. Since proteins reflect disease status directly, proteomics has been utilized in biomarker developments for HCC. In particular, proteomics coupled with liquid chromatography-mass spectrometer (LC-MS) methods facilitate the process of discovering biomarker candidates for diagnosis, prognosis, and therapeutic strategies.</div><div>In this work, we investigated LC-MS-based proteomics methods through recent reference reviews, with a particular focus on sample preparation and LC-MS methods appropriate for the discovery of HCC biomarkers and their clinical applications.</div><div>We classified proteomics studies of HCC according to sample types, and we examined the coverage of protein biomarker candidates based on LC-MS methods in relation to study scales and goals. Comprehensively, we proposed protein biomarker candidates categorized by sample types and biomarker types for appropriate clinical use.</div><div>In this review, we summarized recent LC-MS-based proteomics studies on HCC and proposed potential protein biomarkers. Our findings are expected to expand the understanding of HCC pathogenesis and enhance the efficiency of HCC diagnosis and prognosis, thereby contributing to improved patient outcomes.</div></div>","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":"48 1","pages":"Article 100752"},"PeriodicalIF":4.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11743302/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141431303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatocyte nuclear factor 4 located in different developmental stages of Schistosoma japonicum and involved in important metabolic pathways","authors":"Kaijuan Wu ,&nbsp;Shuaiqin Huang ,&nbsp;Yiming Zhao ,&nbsp;Abdulrahim Umar ,&nbsp;Hao Chen ,&nbsp;Zheng Yu ,&nbsp;Jing Huang","doi":"10.1016/j.bj.2024.100726","DOIUrl":"10.1016/j.bj.2024.100726","url":null,"abstract":"<div><h3>Background</h3><div>Nuclear receptors (NRs) are vital for regulating gene expression in organisms. Hepatocyte nuclear factor 4 (HNF4), a class of NRs, participates in blood feeding and intestinal maintenance in schistosomes. However, there are limited researches on the molecular and functional characterization of HNF4 in Schistosoma japonicum (S. japonicum).</div></div><div><h3>Methods</h3><div>Highly specific polyclonal antibodies were generated to analyze the expression and tissue localization of S. japonicum HNF4 (SjHNF4). The potential biological functions of SjHNF4 were characterized by transcriptome and pull-down analyses. Subsequently, enrichment analysis was performed to identify the specific signaling pathways linked to SjHNF4.</div></div><div><h3>Results</h3><div>The SjHNF4 protein was expressed heterologously and purified successfully. High purity and high potency polyclonal antibodies were further prepared. The expression of SjHNF4 was higher in female compared to male worms at both transcriptional and protein levels. Female worms expressed SjHNF4 in their perithecium, reproductive system, and certain parts of the intestinal tissues. SjHNF4 was also detected in the perithecium of male worms, as well as in the head, body of cercariae, and eggs. Furthermore, our findings highlighted the potential role of SjHNF4 in blood feeding and its interaction with crucial pathways such as glucose metabolism, lipid metabolism, and nucleotide metabolism.</div></div><div><h3>Conclusions</h3><div>This study shed light on the localization of SjHNF4 in different life stages of S. japonicum, particularly associated with the female schistosomes. A strong correlation was observed between SjHNF4 and essential metabolic pathways. These findings laid a solid groundwork for the research on the relationship between NRs and schistosomes.</div></div>","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":"48 1","pages":"Article 100726"},"PeriodicalIF":4.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140770088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect and mechanism of astragalus polysaccharides on T cells and macrophages in inhibiting prostate cancer","authors":"Ching-Yuan Wu ,&nbsp;Yao-Hsu Yang ,&nbsp;Yu-Shih Lin ,&nbsp;Li-Hsin Shu ,&nbsp;Hung-Te Liu ,&nbsp;Chung-Kuang Lu ,&nbsp;Yu-Huei Wu ,&nbsp;Yu-Heng Wu","doi":"10.1016/j.bj.2024.100741","DOIUrl":"10.1016/j.bj.2024.100741","url":null,"abstract":"<div><h3>Background</h3><div>The impact and underlying mechanisms of astragalus polysaccharide (APS) on prostate cancer, particularly its role in immunomodulation, remain inadequately elucidated.</div></div><div><h3>Methods</h3><div>This study employed the XTT assay for assessing proliferation in prostate cancer cells and macrophages. T cell proliferation was determined using the Carboxyfluorescein diacetate succinimidyl ester labeling assay. APS’s effect on T cells and macrophages was scrutinized via flow cytometry, Western blot analysis, ELISA, quantitative PCR and cytokine membrane arrays. The effect of APS on interaction between PD-L1 and PD-1 was investigated by the PD-L1/PD-1 homogeneous assay. Additionally, the impact of conditioned medium from T cells and macrophages on PC-3 cell migration was explored through migration assays.</div></div><div><h3>Results</h3><div>It was observed that APS at concentrations of 1 and 5 mg/mL enhanced the proliferation of CD8⁺ T cells. At a concentration of 5 mg/mL, APS activated both CD4⁺ and CD8⁺ T cells, attenuated PD-L1 expression in prostate cancer cells stimulated with interferon gamma (IFN-γ) or oxaliplatin, and moderately decreased the population of PD-1+ CD4⁺ and PD-1+ CD8⁺ T cells. Furthermore, APS at this concentration impeded the interaction between PD-L1 and PD-1, inhibited the promotion of prostate cancer migration mediated by RAW 264.7 cells, THP-1 cells, CD4⁺ T cells, and CD8⁺ T cells, and initiated apoptosis in prostate cancer cells treated with conditioned medium from APS (5 mg/mL)-treated CD8⁺ T cells, RAW 264.7 cells, or THP-1 cells.</div></div><div><h3>Conclusion</h3><div>The findings indicate a potential role of 5 mg/mL APS in modulating the PD-1/PD-L1 pathway and influencing the immune response, encompassing T cells and macrophages. Consequently, further in vivo research is recommended to assess the efficacy of APS.</div></div>","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":"48 1","pages":"Article 100741"},"PeriodicalIF":4.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773229/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140856037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mitochondrial dysfunction route as a possible biomarker and therapy target for human cancer","authors":"Rawan Al-Faze ,&nbsp;Hoda A. Ahmed ,&nbsp;Mohamed A. El-Atawy ,&nbsp;Hayat Zagloul ,&nbsp;Eida M. Alshammari ,&nbsp;Mariusz Jaremko ,&nbsp;Abdul-Hamid Emwas ,&nbsp;Gehan M. Nabil ,&nbsp;Demiana H. Hanna","doi":"10.1016/j.bj.2024.100714","DOIUrl":"10.1016/j.bj.2024.100714","url":null,"abstract":"<div><div>Mitochondria are vital organelles found within living cells and have signalling, biosynthetic, and bioenergetic functions. Mitochondria play a crucial role in metabolic reprogramming, which is a characteristic of cancer cells and allows them to ensure a steady supply of proteins, nucleotides, and lipids to enable rapid proliferation and development. Their dysregulated activities have been associated with the growth and metastasis of different kinds of human cancer, particularly ovarian carcinoma. In this review, we briefly demonstrated the modified mitochondrial function in cancer, including mutations in mitochondrial DNA (mtDNA), reactive oxygen species (ROS) production, dynamics, apoptosis of cells, autophagy, and calcium excess to maintain cancer genesis, progression, and metastasis. Furthermore, the mitochondrial dysfunction pathway for some genomic, proteomic, and metabolomics modifications in ovarian cancer has been studied. Additionally, ovarian cancer has been linked to targeted therapies and biomarkers found through various alteration processes underlying mitochondrial dysfunction, notably targeting (ROS), metabolites, rewind metabolic pathways, and chemo-resistant ovarian carcinoma cells.</div></div>","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":"48 1","pages":"Article 100714"},"PeriodicalIF":4.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140055158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reflecting on the 1998 enterovirus outbreak: A 25-year retrospective and learned lessons","authors":"Peng-Nien Huang ,&nbsp;Shao-Hsuan Hsia ,&nbsp;Kuan-Ying Arthur Huang ,&nbsp;Chih-Jung Chen ,&nbsp;En-Tzu Wang ,&nbsp;Shin-Ru Shih ,&nbsp;Tzou-Yien Lin","doi":"10.1016/j.bj.2024.100715","DOIUrl":"10.1016/j.bj.2024.100715","url":null,"abstract":"<div><div>Enterovirus A71 (EV-A71) infections are a major Asia-Pacific health issue. However, this infection can cause serious and potentially fatal neurological issues. We attempt to explain EV-A71's molecular virology, epidemiology, and recombination events in this review. The clinical and neurological signs of EV-A71 infections are well documented. The review discusses EV-A71 central nervous system infections' causes, diagnostic criteria, treatment choices, and prognosis. Some consequences are aseptic meningitis, acute flaccid paralysis, and acute transverse myelitis. These problems' pathophysiology and EV-A71's central nervous system molecular processes are examined in the review. EV-A71 infections must be diagnosed accurately for therapy. No particular antiviral medications exist for EV-A71 infections, thus supportive care is the main treatment. The study emphasises addressing symptoms including temperature, dehydration, and pain to ease suffering. EV-A71 CNS infections have different prognoses depending on severity. The review discusses long-term effects and neurological sequelae of EV-A71 infections. In conclusion, Asia-Pacific public health is threatened by EV-A71 infections. This review helps prevent, diagnose, and treat EV-A71 infections by addressing the mechanisms, diagnostic criteria, treatment choices, and prognosis. This study fully examines the challenges and considerations of managing and treating EV-A71 infections. It also recommends future research and development to generate effective viral infection treatments.</div></div>","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":"48 1","pages":"Article 100715"},"PeriodicalIF":4.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11751406/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140139817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Good things come in small packages: The discovery of small RNAs in the smallest animal model","authors":"Chung-Pei Ma ,&nbsp;Szecheng J. Lo ,&nbsp;Bertrand Chin-Ming Tan","doi":"10.1016/j.bj.2025.100832","DOIUrl":"10.1016/j.bj.2025.100832","url":null,"abstract":"<div><div>The 2024 Nobel Prize in Physiology or Medicine has been awarded to two pioneering researchers, Victor Ambros and Gary Ruvkun, marking the fourth time research using Caenorhabditis elegans (C. elegans) has received this prestigious recognition. With a rapid life cycle of just 3.5 days and four distinct larval stages, C. elegans serves as an ideal model for exploring complex genetic mechanisms, particularly heterochronic gene regulation. Ambros and Ruvkun's groundbreaking work on lin-4 and lin-14 genes in C. elegans revealed that lin-4 functions as a 22-nucleotide small RNA—now known as a microRNA (miRNA)—that binds complementarily to the 3′ UTR of lin-14 mRNA, effectively inhibiting LIN-14 protein synthesis. This discovery was the first demonstration of miRNA in post-transcriptional gene regulation, a finding that has since reshaped our understanding of genetic regulation across species. Their research on small RNAs in C. elegans not only opened a new paradigm in molecular biology but also highlighted the power of this model organism in uncovering universal biological principles.</div></div>","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":"48 1","pages":"Article 100832"},"PeriodicalIF":4.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143424943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular diagnosis of nasopharyngeal carcinoma: Past and future","authors":"Cheng-Lung Hsu ,&nbsp;Yu-Sun Chang ,&nbsp;Hsin-Pai Li","doi":"10.1016/j.bj.2024.100748","DOIUrl":"10.1016/j.bj.2024.100748","url":null,"abstract":"<div><div>Nasopharyngeal carcinoma (NPC) is a malignant tumor originated from the nasopharynx epithelial cells and has been linked with Epstein-Barr virus (EBV) infection, dietary habits, environmental and genetic factors. It is a common malignancy in Southeast Asia, especially with gender preference among men. Due to its non-specific symptoms, NPC is often diagnosed at a late stage. Thus, the molecular diagnosis of NPC plays a crucial role in early detection, treatment selection, disease monitoring, and prognosis prediction. This review aims to provide a summary of the current state and the latest emerging molecular diagnostic techniques for NPC, including EBV-related biomarkers, gene mutations, liquid biopsy, and DNA methylation. Challenges and potential future directions of NPC molecular diagnosis will be discussed.</div></div>","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":"48 1","pages":"Article 100748"},"PeriodicalIF":4.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141136343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}